Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor response rate at the 8mg/kg dose. The drug targets the B7-H3 protein and compares favorably to a rival treatment by Merck. Jefferies estimates peak global sales of $3 billion, with potential use in other cancers and combination therapies. The durability of the drug's effect is still being studied as progression-free survival data is pending.
GSK shares are trading at USD 49.58 on Pluang, showing a modest 0.14% gain as of Oct 19, 2026 18:12 WIB. The stock has a dividend yield of 3.67% and a market cap of $99.04 billion, reflecting steady investor interest amid recent positive news.
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
GSK plc shows strong progress in its oncology pipeline, highlighted by positive phase 1 results for Mo-Rez in treating platinum-resistant ovarian and endometrial cancers. These promising outcomes support plans for five global pivotal phase 3 trials s...
